

Special Issue

Gastrointestinal Cancers: Molecular Mechanisms and Therapies

Message from the Guest Editors

This Special Issue on “Gastrointestinal Cancers: Molecular Mechanisms and Therapies” will mainly focus on analyzing present and future approaches for the treatment of gastrointestinal cancer patients, with a glimpse of novel perspectives and future challenges in clinical practice. Gastrointestinal cancers are one of the most common worldwide cause of cancer-related death. In the last decade, significant improvements have been made in the prognosis of patients with gastrointestinal cancers deriving from the development of modern tailored therapies, which include cytotoxic drugs, targeted therapies, and immunotherapy. Recently, emerging and novel biomarkers have been identified and validated with a huge impact on patients’ outcomes and improving the treatment landscape. Despite these advances, gastrointestinal cancers still represent a major public health problem worldwide; hence, it is mandatory to develop novel therapeutic approaches for patients affected by those cancers. We cordially invite experts in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Guest Editors

Dr. Seok-Jun Kim

Dr. Valentina Calò

Dr. Marta Castiglia

Dr. Nadia Barraco

Deadline for manuscript submissions

closed (15 June 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/67938

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).